Skin Research Institute | Clinical Research Site
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General
Type of Participant and Disease Characteristics
Exclusion criteria
Medical Conditions
Other protocol defined Inclusion/Exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
258 participants in 2 patient groups
Loading...
Central trial contact
Saskia Benner
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal